Clinical trial · Interventional
Assessing the Impact of Dosage Frequency of Propranolol on Sleep Patterns in Patients With Infantile Hemangiomas
NCT05479123CI-TRIAL-00105450terminatedPhase 4Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): due to lack of recruitment and follow up compliance
Summary
Brief summary (as posted)
The purpose of this study is to assess the baseline sleep pattern disruption for patients starting oral propranolol at the standard BID dosing regimen compared to the control (timolol) group and to determine if there is a significant improvement in the sleep patterns in infants taking oral propranolol on the TID dosing regimen versus the control (timolol) group
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Infantile Hemangioma | Infantile Hemangioma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Propranolol three times a day | Drug | — | UNRESOLVED |
| Propranolol twice a day | Drug | — | UNRESOLVED |
| Timolol | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- ter in die (TID)three times a day
- interventionNames
- Drug: Propranolol three times a day
- type
- EXPERIMENTAL
- label
- bis in die (BID)twice a day
- interventionNames
- Drug: Propranolol twice a day
- type
- ACTIVE_COMPARATOR
- label
- Control
- interventionNames
- Drug: Timolol
Primary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 18 Months
Show eligibility criteria text
Inclusion Criteria: * clinically diagnosed hemangiomas. * English or Spanish speaking only Exclusion Criteria: * Parents who do not consent to the study. * Significant cardiac or pulmonary disease who are unable to tolerate oral propranolol
References
Publications (0)
Data not yet available
No reference posted for this study.